This is a table of type proper and their frequencies. Use it to search & browse the list to learn more about your study carrel.
| proper | frequency |
|---|---|
| AE | 859 |
| COVID-19 | 661 |
| BMI | 323 |
| SARS | 301 |
| T2DM | 299 |
| CoV-2 | 225 |
| Diabetes | 210 |
| mg | 206 |
| MS | 206 |
| Health | 199 |
| China | 189 |
| India | 175 |
| IR | 171 |
| NAFLD | 158 |
| HOMA | 149 |
| HbA1c | 140 |
| C | 140 |
| University | 121 |
| ACE2 | 112 |
| HDL | 109 |
| der | 101 |
| MetS | 97 |
| Disease | 96 |
| CRP | 96 |
| dl | 84 |
| Wuhan | 84 |
| NASH | 84 |
| Study | 82 |
| IL-6 | 81 |
| HCQ | 80 |
| DM | 80 |
| A1c | 79 |
| Coronavirus | 78 |
| CI | 77 |
| ICU | 76 |
| Association | 76 |
| mmol | 74 |
| National | 71 |
| Clinical | 70 |
| T | 69 |
| CAD | 67 |
| Hospital | 66 |
| II | 64 |
| IGT | 64 |
| America | 64 |
| HFD | 63 |
| Brazil | 63 |
| metformin | 62 |
| Insulin | 61 |
| CVD | 61 |
| OGTT | 60 |
| Italy | 60 |
| Care | 59 |
| TNF | 58 |
| South | 58 |
| IFG | 58 |
| Covid-19 | 57 |
| PCOS | 55 |
| GDM | 54 |
| Latin | 54 |
| Table | 53 |
| TB | 53 |
| mit | 51 |
| WC | 51 |
| PCR | 49 |
| International | 49 |
| Review | 49 |
| meta | 48 |
| Group | 48 |
| Curcumin | 48 |
| UK | 47 |
| PA | 47 |
| GLP-1 | 47 |
| Angiotensin | 46 |
| American | 46 |
| J | 46 |
| kg | 46 |
| World | 46 |
| von | 44 |
| Research | 44 |
| Prevention | 44 |
| Control | 44 |
| Medicine | 43 |
| B | 43 |
| sha | 42 |
| Education | 42 |
| Risk | 41 |
| ROS | 41 |
| Management | 41 |
| BP | 41 |
| Medical | 40 |
| USA | 39 |
| TG | 39 |
| CoV | 38 |
| DFD | 38 |
| Program | 36 |
| Organization | 36 |
| LDL | 36 |
| Fig | 36 |
| ELISA | 36 |
| Diabetic | 36 |
| einer | 35 |
| Syndrome | 35 |
| hs | 34 |
| United | 34 |
| March | 34 |
| Texas | 33 |
| IDF | 33 |
| M. | 32 |
| IMT | 32 |
| Analysis | 32 |
| Mexico | 32 |
| Patients | 32 |
| Center | 32 |
| Treatment | 31 |
| Outcomes | 31 |
| Liver | 31 |
| HIV | 31 |
| Background | 31 |
| SBP | 31 |
| LatAm | 30 |
| Institute | 30 |
| Europe | 30 |
| D | 30 |
| ADA | 30 |
| Federation | 29 |
| FMD | 29 |
| A | 29 |
| Glycemic | 28 |
| DOI | 28 |
| East | 28 |
| WHR | 28 |
| New | 27 |
| Australia | 27 |
| CKD | 27 |
| COVID | 27 |
| Hydroxychloroquine | 27 |
| Human | 27 |
| Public | 27 |
| SD | 27 |
| System | 27 |
| Type | 27 |
| α | 27 |
| ml | 26 |
| States | 26 |
| Impact | 26 |
| Foot | 26 |
| A. | 26 |
| ACE | 25 |
| CGM | 25 |
| C. | 25 |
| GIP | 25 |
| Middle | 25 |
| III | 25 |
| bei | 25 |
| Glucose | 24 |
| ng | 24 |
| hyperglycaemia | 24 |
| Nutrition | 24 |
| Mellitus | 24 |
| IV | 24 |
| FPG | 24 |
| Chinese | 24 |
| Cardiovascular | 24 |
| Adults | 23 |
| G | 23 |
| LPS | 23 |
| Meta | 23 |
| IFN | 23 |
| Metformin | 23 |
| Republic | 23 |
| S | 23 |
| S. | 23 |
| WHO | 23 |
| den | 23 |
| MERS | 22 |
| FFA | 22 |
| FBG | 22 |
| European | 22 |
| CD4 | 22 |
| B. | 22 |
| Akt | 22 |
| AH | 22 |
| HR | 21 |
| Metabolic | 21 |
| L | 21 |
| Systematic | 21 |
| Chronic | 21 |
| COPD | 21 |
| Novel | 21 |
| NGT | 21 |
| VO | 21 |
| PPAR | 21 |
| Survey | 21 |
| Typ-1-Diabetes | 21 |
| • | 21 |
| eine | 21 |
| liraglutide | 21 |
| Spain | 21 |
| Denmark | 20 |
| ATP | 20 |
| DKA | 20 |
| < | 20 |
| Enzyme | 20 |
| Nonalcoholic | 20 |
| US | 20 |
| Factors | 20 |
| I | 19 |
| BG | 19 |
| City | 19 |
| Diseases | 19 |
| E. | 19 |
| Healthy | 19 |
| RNA | 19 |
| Receptor | 19 |
| SPSS | 19 |
| Trial | 19 |
| auf | 19 |
| des | 19 |
| Development | 18 |
| Evaluation | 18 |
| F | 18 |
| DM2 | 18 |
| HLA | 18 |
| Germany | 18 |
| PD | 18 |
| microalbuminuria | 18 |
| Studie | 18 |
| Time | 18 |
| U.S. | 18 |
| Self | 18 |
| Malta | 17 |
| AMI | 17 |
| Characteristics | 17 |
| DPP4 | 17 |
| GSH | 17 |
| Global | 17 |
| IC | 17 |
| Low | 17 |
| IL-18 | 17 |
| Pacific | 17 |
| Society | 17 |
| WHtR | 17 |
| dass | 17 |
| lmol | 17 |
| steatohepatitis | 17 |
| und | 17 |
| zu | 17 |
| SOD | 17 |
| Department | 16 |
| France | 16 |
| Fatty | 16 |
| Effect | 16 |
| ARB | 16 |
| December | 16 |
| DPP | 16 |
| BS | 16 |
| April | 16 |
| LMIC | 16 |
| PLWD | 16 |
| PWV | 16 |
| Taiwan | 16 |
| Patient | 16 |
| werden | 16 |
| VEGF | 16 |
| UA | 16 |
| γ | 16 |
| T2D. | 16 |
| Social | 16 |
| STAT3 | 16 |
| Regional | 16 |
| Region | 16 |
| MSG | 15 |
| ACR | 15 |
| Ace2 | 15 |
| Based | 15 |
| DBP | 15 |
| DPN | 15 |
| England | 15 |
| Indians | 15 |
| January | 15 |
| Japan | 15 |
| RT | 15 |
| May | 15 |
| MetS. | 15 |
| NCEP | 15 |
| OC | 15 |
| R. | 15 |
| Steatohepatitis | 15 |
| Use | 15 |
| auch | 15 |
| dem | 15 |
| mRNA | 15 |
| HF | 14 |
| Endocrinology | 14 |
| Heart | 14 |
| February | 14 |
| Korea | 14 |
| Drug | 14 |
| Central | 14 |
| CT | 14 |
| Americans | 14 |
| Iran | 14 |
| E | 14 |
| Obesity | 14 |
| Resistance | 14 |
| P. | 14 |
| p.a | 14 |
| Wistar | 14 |
| chemerin | 14 |
| peptide-1 | 14 |
| 14 | |
| RR | 14 |
| Practice | 14 |
| Clinic | 13 |
| IL-8 | 13 |
| IHD | 13 |
| Hp | 13 |
| H. | 13 |
| DN | 13 |
| Committee | 13 |
| AST | 13 |
| Chi | 13 |
| CD8 | 13 |
| BNP | 13 |
| Aim | 13 |
| Index | 13 |
| ADMA | 13 |
| IU | 13 |
| Hg | 13 |
| J. | 13 |
| ROC | 13 |
| Lipid | 13 |
| zur | 13 |
| Whitney | 13 |
| Therapy | 13 |
| SAT | 13 |
| Randomized | 13 |
| RYGB | 13 |
| Sars | 13 |
| Primary | 13 |
| Poland | 13 |
| OPG | 13 |
| Model | 13 |
| Mann | 13 |
| M | 13 |
| Cohort | 12 |
| Internal | 12 |
| Innen | 12 |
| Hepatic | 12 |
| HbA1C | 12 |
| HbA | 12 |
| Guidelines | 12 |
| Guatemala | 12 |
| GBP | 12 |
| Epidemiology | 12 |
| ANA | 12 |
| Clin | 12 |
| Centre | 12 |
| CRF | 12 |
| COVID19 | 12 |
| C.I. | 12 |
| BA | 12 |
| Adiponectin | 12 |
| AMPK | 12 |
| L. | 12 |
| June | 12 |
| Asia | 12 |
| MMP-9 | 12 |
| Sweden | 12 |
| NLR | 12 |
| m² | 12 |
| multimorbidity | 12 |
| lg | 12 |
| nicht | 12 |
| kcal | 12 |
| das | 12 |
| Technology | 12 |
| TC | 12 |
| hydroxychloroquine | 12 |
| September | 12 |
| Romania | 12 |
| RA | 12 |
| Puerto | 12 |
| Peru | 12 |
| Pandemic | 12 |
| PON1 | 12 |
| SNP | 12 |
| PE | 12 |
| GH | 11 |
| FBS | 11 |
| FM | 11 |
| Faculty | 11 |
| ISI | 11 |
| Gestational | 11 |
| IL-4 | 11 |
| IRS-1 | 11 |
| Delhi | 11 |
| EC | 11 |
| Adult | 11 |
| Data | 11 |
| Cox | 11 |
| College | 11 |
| COV | 11 |
| CD36 | 11 |
| Burden | 11 |
| Body | 11 |
| Blood | 11 |
| Ang | 11 |
| Jordan | 11 |
| ARDS | 11 |
| Intensive | 11 |
| Glucagon | 11 |
| LC | 11 |
| SHR | 11 |
| Lancet | 11 |
| zone | 11 |
| nmol | 11 |
| microRNA | 11 |
| diabetes | 11 |
| cardiometabolic | 11 |
| Y | 11 |
| Unit | 11 |
| TCF7L2 | 11 |
| SUGAR | 11 |
| glycemic | 11 |
| Respiratory | 11 |
| NK | 11 |
| MG | 11 |
| Peripheral | 11 |
| Mycobacterium | 11 |
| ND | 11 |
| NPDR | 11 |
| North | 11 |
| OxLDL | 11 |
| PAI-1 | 11 |
| H1N1 | 10 |
| Infection | 10 |
| High | 10 |
| IL-1β | 10 |
| IQR | 10 |
| Immune | 10 |
| Implementation | 10 |
| MGO | 10 |
| K. | 10 |
| Munc18c | 10 |
| MDA | 10 |
| Maria | 10 |
| Mechanisms | 10 |
| Exercise | 10 |
| G. | 10 |
| Bcl-2 | 10 |
| Effectiveness | 10 |
| EU-28 | 10 |
| DPP-4 | 10 |
| DGEP | 10 |
| DC | 10 |
| Czech | 10 |
| Controlled | 10 |
| Community | 10 |
| Cholesterol | 10 |
| CGMS | 10 |
| Argentina | 10 |
| Aghdam | 10 |
| ALT | 10 |
| 8) | 10 |
| Mets | 10 |
| PRE | 10 |
| NDP | 10 |
| Rico | 10 |
| NF | 10 |
| sich | 10 |
| interleukin-6 | 10 |
| einem | 10 |
| ein | 10 |
| Wang | 10 |
| TT | 10 |
| TBARS | 10 |
| Support | 10 |
| Springer | 10 |
| Southern | 10 |
| Singapore | 10 |
| Sciences | 10 |
| U | 10 |
| Renin | 10 |
| Physical | 10 |
| Ramadan | 10 |
| OB | 10 |
| Online | 10 |
| Pathway | 10 |
| Paulo | 10 |
| NT | 10 |
| Portugal | 10 |
| Pract | 10 |
| Prediabetes | 10 |
| Pressure | 10 |
| PubMed | 10 |
| Plasma | 10 |
| English | 9 |
| HCC | 9 |
| Estonia | 9 |
| FXR | 9 |
| GD | 9 |
| General | 9 |
| Government | 9 |
| H | 9 |
| HBV | 9 |
| I. | 9 |
| Handshake | 9 |
| Hb | 9 |
| Hong | 9 |
| IL-10 | 9 |
| IL-2 | 9 |
| Inhibitor | 9 |
| Jahr | 9 |
| Jahre | 9 |
| Ergebnisse | 9 |
| BF | 9 |
| Der | 9 |
| Depression | 9 |
| /m | 9 |
| A1 | 9 |
| Abstract | 9 |
| Article | 9 |
| Assessment | 9 |
| Kong | 9 |
| BTH | 9 |
| Bulgaria | 9 |
| CHD | 9 |
| CMK | 9 |
| CMR | 9 |
| COVID‐19 | 9 |
| Chloroquine | 9 |
| Comparison | 9 |
| D. | 9 |
| DAG | 9 |
| Dawley | 9 |
| Klebsiella | 9 |
| Introduction | 9 |
| MDI | 9 |
| durch | 9 |
| TMPRSS2 | 9 |
| UKPDS | 9 |
| Western | 9 |
| als | 9 |
| association | 9 |
| candesartan | 9 |
| control | 9 |
| db | 9 |
| east | 9 |
| Sprague | 9 |
| mass | 9 |
| multicentre | 9 |
| nach | 9 |
| nan | 9 |
| vildagliptin | 9 |
| wird | 9 |
| wurde | 9 |
| MI | 9 |
| Staphylococcus | 9 |
| ± | 9 |
| SI | 9 |
| OR | 9 |
| MODY | 9 |
| Metab | 9 |
| Myocardin | 9 |
| Myr | 9 |
| NGAL | 9 |
| NSTEMI | 9 |
| Nature | 9 |
| NIDDM | 9 |
| Objective | 9 |
| Prevalence | 9 |
| Pearson | 9 |
| RFLP | 9 |
| Questionnaire | 9 |
| Report | 9 |
| Pregnancy | 9 |
| Placebo | 9 |
| SC | 9 |
| Hypoglycaemia | 8 |
| F. | 8 |
| Family | 8 |
| Fibrosis | 8 |
| GGT | 8 |
| HDM | 8 |
| HTGpos | 8 |
| Healthcare | 8 |
| LDM | 8 |
| IGF-1 | 8 |
| IQ | 8 |
| Infections | 8 |
| Inhibitors | 8 |
| Interventions | 8 |
| Ireland | 8 |
| Kingdom | 8 |
| Kuwait | 8 |
| Endocrine | 8 |
| Examination | 8 |
| CR | 8 |
| Efficacy | 8 |
| Africa | 8 |
| London | 8 |
| AG | 8 |
| AS | 8 |
| ATPIII | 8 |
| AUC | 8 |
| Accepted | 8 |
| Activity | 8 |
| Associated | 8 |
| Doppler | 8 |
| BMSD | 8 |
| Cardiology | 8 |
| Commons | 8 |
| Complications | 8 |
| Creative | 8 |
| DR | 8 |
| Danish | 8 |
| Latvia | 8 |
| BAI | 8 |
| NHS | 8 |
| Value | 8 |
| WD | 8 |
| WPR | 8 |
| Weight | 8 |
| York | 8 |
| antihyperglycemic | 8 |
| apelin | 8 |
| biennia | 8 |
| hyperuricemia | 8 |
| β | 8 |
| max | 8 |
| st | 8 |
| sulfonylureas | 8 |
| urotensin | 8 |
| vivo | 8 |
| west | 8 |
| über | 8 |
| NKT | 8 |
| Virus | 8 |
| sitagliptin | 8 |
| Ulcers | 8 |
| QUICKI | 8 |
| Trials | 8 |
| Nampt | 8 |
| Neuropathy | 8 |
| Neutrophil | 8 |
| P | 8 |
| Physiology | 8 |
| Practical | 8 |
| Protein | 8 |
| Patienten | 8 |
| Quality | 8 |
| RHR | 8 |
| RMR | 8 |
| Sao | 8 |
| School | 8 |
| Service | 8 |
| State | 8 |
| Studies | 8 |
| EASD | 7 |
| Fetal | 7 |
| FTO | 7 |
| FGR | 7 |
| FD | 7 |
| DNL | 7 |
| Dyslipidemia | 7 |
| Dr. | 7 |
| DCM | 7 |
| DJBL | 7 |
| GA | 7 |
| Finland | 7 |
| Hubei | 7 |
| GK | 7 |
| Greece | 7 |
| Growth | 7 |
| Gruppe | 7 |
| HG | 7 |
| HIV+ | 7 |
| HepG2 | 7 |
| Hispanics | 7 |
| Honduras | 7 |
| Hungary | 7 |
| Hypertension | 7 |
| Colombia | 7 |
| Corona | 7 |
| AO | 7 |
| Chile | 7 |
| Austria | 7 |
| A&M | 7 |
| ACE-2 | 7 |
| ACEI | 7 |
| AL | 7 |
| ANG | 7 |
| ANOVA | 7 |
| Inhibition | 7 |
| Advanced | 7 |
| Alcohol | 7 |
| Apo | 7 |
| Atlas | 7 |
| Basal | 7 |
| Chemerin | 7 |
| Belgium | 7 |
| Burkholderia | 7 |
| CA | 7 |
| CD | 7 |
| CHO | 7 |
| COX-2 | 7 |
| CSII | 7 |
| Canada | 7 |
| Cardiac | 7 |
| Case | 7 |
| Cer | 7 |
| Influenza | 7 |
| ECs | 7 |
| Initiative | 7 |
| TBX20 | 7 |
| Tandem | 7 |
| Teplizumab | 7 |
| Therapie | 7 |
| Triphala | 7 |
| Uruguay | 7 |
| Venezuela | 7 |
| Visfatin | 7 |
| 7 | |
| West | 7 |
| Wilcoxon | 7 |
| Women | 7 |
| analysis | 7 |
| aus | 7 |
| caspase-3 | 7 |
| diabetischen | 7 |
| dieser | 7 |
| incretin | 7 |
| insulinemia | 7 |
| lispro | 7 |
| min | 7 |
| monocyte | 7 |
| nur | 7 |
| ob | 7 |
| oder | 7 |
| Jun | 7 |
| TE | 7 |
| disease | 7 |
| T1 | 7 |
| NAMPT | 7 |
| Kontrollgruppe | 7 |
| Stress | 7 |
| LF | 7 |
| Life | 7 |
| Lombardy | 7 |
| MOP | 7 |
| Major | 7 |
| Mexican | 7 |
| Mortality | 7 |
| N | 7 |
| N. | 7 |
| MCP-1 | 7 |
| Netherlands | 7 |
| SDMA | 7 |
| Pathogenesis | 7 |
| Smart | 7 |
| STZ | 7 |
| SREBP-1c | 7 |
| SPT | 7 |
| S1PR1 | 7 |
| RAS | 7 |
| R | 7 |
| Scientific | 7 |
| HPLC | 6 |
| Guidance | 6 |
| Fisher | 6 |
| GWG | 6 |
| G6PD | 6 |
| HTN | 6 |
| Früherkennung | 6 |
| Front | 6 |
| FGM | 6 |
| FasL | 6 |
| Fas | 6 |
| FK866 | 6 |
| Expression | 6 |
| Expert | 6 |
| Ethics | 6 |
| Home | 6 |
| Effects | 6 |
| Erkrankung | 6 |
| Helsinki | 6 |
| Israel | 6 |
| Hyperglycaemia | 6 |
| Kidney | 6 |
| Lp(a | 6 |
| ER | 6 |
| Lithuania | 6 |
| Latinos | 6 |
| LVDD | 6 |
| LETO | 6 |
| L1 | 6 |
| Intervention | 6 |
| IAPP | 6 |
| Inpatient | 6 |
| IS | 6 |
| INS-1E | 6 |
| IN | 6 |
| ILC2s | 6 |
| IL-22 | 6 |
| IL-17 | 6 |
| ET-1 | 6 |
| BGL | 6 |
| EHR | 6 |
| Antioxidant | 6 |
| CREB | 6 |
| CC | 6 |
| Blockers | 6 |
| Behavior | 6 |
| August | 6 |
| Asians | 6 |
| Application | 6 |
| Anti | 6 |
| Cell | 6 |
| Agency | 6 |
| Age | 6 |
| Action | 6 |
| AIM | 6 |
| ADF | 6 |
| AC | 6 |
| MET | 6 |
| CTRP-3 | 6 |
| Children | 6 |
| EGCG | 6 |
| Cross | 6 |
| Doogh | 6 |
| Diet | 6 |
| Declaration | 6 |
| DPPIV | 6 |
| DMH | 6 |
| DLI | 6 |
| DEXA | 6 |
| Cov-2 | 6 |
| Closed | 6 |
| Council | 6 |
| Costa | 6 |
| Communities | 6 |
| CoViDiab | 6 |
| CoV2 | 6 |
| Co | 6 |
| Cluj | 6 |
| MBF | 6 |
| PWS | 6 |
| MMP-2 | 6 |
| SM | 6 |
| Watson | 6 |
| Vascular | 6 |
| Union | 6 |
| UPR | 6 |
| UAG | 6 |
| Trends | 6 |
| Tg | 6 |
| Telemedicine | 6 |
| Team | 6 |
| TSH | 6 |
| TGF | 6 |
| T. | 6 |
| Sydney | 6 |
| Supplementation | 6 |
| Studien | 6 |
| Sea | 6 |
| Se | 6 |
| Wnt | 6 |
| Yakult | 6 |
| Zealand | 6 |
| proBNP | 6 |
| −0.12 | 6 |
| MONICA | 6 |
| ® | 6 |
| waren | 6 |
| vaspin | 6 |
| sera | 6 |
| secretase | 6 |
| mehr | 6 |
| antidiabetic | 6 |
| mHealth | 6 |
| lymphopenia | 6 |
| ist | 6 |
| iptakalim | 6 |
| group | 6 |
| gr | 6 |
| exenatide | 6 |
| SW | 6 |
| dysmetabolic | 6 |
| SGLT-2 | 6 |
| OSAS | 6 |
| OLETF | 6 |
| OGL | 6 |
| OCA | 6 |
| Nrf2 | 6 |
| Napoca | 6 |
| NS | 6 |
| NADPH | 6 |
| Mouse | 6 |
| Moscow | 6 |
| Monitoring | 6 |
| Ministry | 6 |
| Methods | 6 |
| Melioidosis | 6 |
| Manifestation | 6 |
| SE | 6 |
| MRS | 6 |
| MR | 6 |
| OSA | 6 |
| Multiple | 6 |
| Obex | 6 |
| Potential | 6 |
| SA | 6 |
| Rome | 6 |
| PON2 | 6 |
| Rica | 6 |
| RI | 6 |
| QT | 6 |
| S1 | 6 |
| Q | 6 |
| QOL | 6 |
| Pneumonia | 6 |
| Plantar | 6 |
| Pioglitazone | 6 |
| Paolo | 6 |
| Padova | 6 |
| PPD | 6 |
| Gupta | 5 |
| Godin | 5 |
| Glasgow | 5 |
| GT | 5 |
| HC | 5 |
| GSPE | 5 |
| HT | 5 |
| GSIS | 5 |
| GLP1 | 5 |
| GG | 5 |
| Food | 5 |
| GCK | 5 |
| GBT | 5 |
| GB | 5 |
| Fr1da | 5 |
| Foundation | 5 |
| Figure | 5 |
| Factores | 5 |
| FEV | 5 |
| HW | 5 |
| Ecuador | 5 |
| FDA | 5 |
| HTGC | 5 |
| KO | 5 |
| Haiti | 5 |
| JAK | 5 |
| Liraglutide | 5 |
| EASO | 5 |
| Leptin | 5 |
| Lazio | 5 |
| LXR | 5 |
| LEP | 5 |
| Kupffer | 5 |
| K | 5 |
| July | 5 |
| JAK3 | 5 |
| Irx5 | 5 |
| Hcy | 5 |
| Interventionsgruppe | 5 |
| Institutional | 5 |
| Injury | 5 |
| Infectious | 5 |
| Induced | 5 |
| IgE | 5 |
| IVR | 5 |
| Hypoglycemia | 5 |
| Hs | 5 |
| Hepatitis | 5 |
| EZSCAN | 5 |
| Access | 5 |
| EASL | 5 |
| Activated | 5 |
| Barone | 5 |
| BPA | 5 |
| Axis | 5 |
| Autophagy | 5 |
| Attribution | 5 |
| Approach | 5 |
| Apgar | 5 |
| Andrea | 5 |
| Aldosterone | 5 |
| Administration | 5 |
| Abbott | 5 |
| Deutschland | 5 |
| ATG | 5 |
| APM | 5 |
| ALAD | 5 |
| AKT | 5 |
| AHA | 5 |
| ACEi | 5 |
| ABP | 5 |
| ABI | 5 |
| 1c | 5 |
| Loop | 5 |
| Behandlung | 5 |
| Berlin | 5 |
| Binding | 5 |
| Biochemistry | 5 |
| DIO | 5 |
| D2 | 5 |
| Cyprus | 5 |
| Cushing | 5 |
| Curcuma | 5 |
| Cu | 5 |
| Croatia | 5 |
| CoolSense | 5 |
| Comprehensive | 5 |
| Chen | 5 |
| COVID-19-specific | 5 |
| COV2 | 5 |
| COV-2 | 5 |
| CIMT | 5 |
| CHC | 5 |
| CDL | 5 |
| CCM | 5 |
| C57BL/6 | 5 |
| Bucharest | 5 |
| Bolivia | 5 |
| Biomarkers | 5 |
| Liu | 5 |
| UN | 5 |
| Lund | 5 |
| Total | 5 |
| Wellington | 5 |
| Wales | 5 |
| WHTR | 5 |
| WCI | 5 |
| Vergleich | 5 |
| VPA | 5 |
| VLDL | 5 |
| V. | 5 |
| UMF | 5 |
| Tuberculosis | 5 |
| Third | 5 |
| Stadium | 5 |
| Tehran | 5 |
| TRIMPS | 5 |
| TLC | 5 |
| TIR | 5 |
| TBR | 5 |
| T2 | 5 |
| T1DM | 5 |
| T0 | 5 |
| Systems | 5 |
| Status | 5 |
| X. | 5 |
| adj)OR | 5 |
| administration | 5 |
| bereits | 5 |
| M1 | 5 |
| › | 5 |
| β1 | 5 |
| wurden | 5 |
| vor | 5 |
| visfatin | 5 |
| type | 5 |
| rs7903146 | 5 |
| rs3212780 | 5 |
| rs12255372 | 5 |
| pmol | 5 |
| osteoprotegerin | 5 |
| novo | 5 |
| miR-21 | 5 |
| kann | 5 |
| irisin | 5 |
| hypertriglyceridemia | 5 |
| euthyroid | 5 |
| einen | 5 |
| chloroquine | 5 |
| chi | 5 |
| Statistics | 5 |
| telmisartan | 5 |
| Si | 5 |
| NSEACS | 5 |
| PSA | 5 |
| PRISMA | 5 |
| PLHIV | 5 |
| PGF2a | 5 |
| PAE | 5 |
| PAA | 5 |
| OLTT | 5 |
| Nutritional | 5 |
| November | 5 |
| Nations | 5 |
| NG | 5 |
| PYY | 5 |
| NATG | 5 |
| Molecular | 5 |
| Mice | 5 |
| Medicines | 5 |
| Matsuda | 5 |
| Mahlzeiten | 5 |
| Macrophage | 5 |
| MO | 5 |
| Services | 5 |
| MFR | 5 |
| PUFA | 5 |
| Maternal | 5 |
| Panel | 5 |
| S2 | 5 |
| Score | 5 |
| People | 5 |
| Screening | 5 |
| Science | 5 |
| Saudi | 5 |
| San | 5 |
| SUS | 5 |
| STH | 5 |
| SR | 5 |
| SP | 5 |
| Scale | 5 |
| Rosuvastatin | 5 |
| Profile | 5 |
| Response | 5 |
| Poisson | 5 |
| Placental | 5 |
| Population | 5 |
| QUT | 5 |
| Queensland | 5 |
| Peptide | 5 |
| Related | 5 |
| Future | 4 |
| GBD | 4 |
| GFR | 4 |
| GLP-1(7 | 4 |
| GLP-1ra | 4 |
| GLUT2 | 4 |
| GLUT4 | 4 |
| GSK-3beta | 4 |
| Glycaemic | 4 |
| GSSG | 4 |
| Gait | 4 |
| Genotyping | 4 |
| 4 | |
| HA | 4 |
| HHS | 4 |
| HN | 4 |
| Framework | 4 |
| HS | 4 |
| Han | 4 |
| Function | 4 |
| Ethiopia | 4 |
| Fora | 4 |
| Epidemic | 4 |
| Egypt | 4 |
| Homeostasis | 4 |
| Emergency | 4 |
| Emerging | 4 |
| Empagliflozin | 4 |
| Encuesta | 4 |
| Endoplasmic | 4 |
| Entstehen | 4 |
| Ernährung | 4 |
| Footwear | 4 |
| Ethical | 4 |
| Evidence | 4 |
| FINDRISC | 4 |
| FLD | 4 |
| FO | 4 |
| 4 | |
| Fe | 4 |
| First | 4 |
| Herpes | 4 |
| Karnataka | 4 |
| Hospitalized | 4 |
| Laboratory | 4 |
| Kindern | 4 |
| Knowledge | 4 |
| Korean | 4 |
| LDH | 4 |
| LDN | 4 |
| LHB | 4 |
| LOX-1 | 4 |
| LP | 4 |
| Leisure | 4 |
| Juiz | 4 |
| Lima | 4 |
| Longitudinal | 4 |
| Luca | 4 |
| Lung | 4 |
| Luxembourg | 4 |
| MA | 4 |
| MCA | 4 |
| EU | 4 |
| Kg | 4 |
| Journal | 4 |
| Hypercholesterolemia | 4 |
| Ii | 4 |
| Hypertensives | 4 |
| IHA | 4 |
| IL-13 | 4 |
| IL-5 | 4 |
| ILC1s | 4 |
| IUGR | 4 |
| IWGDF | 4 |
| IgG | 4 |
| Income | 4 |
| Island | 4 |
| Indian | 4 |
| Indonesia | 4 |
| Inflammatory | 4 |
| Information | 4 |
| Infusion | 4 |
| Int | 4 |
| Intake | 4 |
| Interleukin-6 | 4 |
| Ebola | 4 |
| Benedetta | 4 |
| ESR | 4 |
| Authority | 4 |
| Amputationen | 4 |
| An | 4 |
| Angelo | 4 |
| Antonio | 4 |
| Arabia | 4 |
| Area | 4 |
| Atorva | 4 |
| Australian | 4 |
| Awareness | 4 |
| Ameliorates | 4 |
| BFM | 4 |
| BPM | 4 |
| BTM | 4 |
| Bank | 4 |
| Bedouin | 4 |
| Betazellen | 4 |
| Bio | 4 |
| Biology | 4 |
| Americas | 4 |
| Al | 4 |
| Board | 4 |
| APB | 4 |
| MRI | 4 |
| -G174C | 4 |
| A.E. | 4 |
| A9 | 4 |
| AF | 4 |
| ALAT | 4 |
| AMR | 4 |
| ANCOVA | 4 |
| APOA5 | 4 |
| Agatston | 4 |
| APs | 4 |
| AQP7 | 4 |
| AVP | 4 |
| Abb | 4 |
| Academy | 4 |
| Ace | 4 |
| Activation | 4 |
| Afro | 4 |
| Birth | 4 |
| Bonora | 4 |
| EMR | 4 |
| Detection | 4 |
| Consensus | 4 |
| Considerations | 4 |
| Copenhagen | 4 |
| County | 4 |
| DNP | 4 |
| DPV | 4 |
| Death | 4 |
| Delivery | 4 |
| Diabetologe | 4 |
| Comorbid | 4 |
| Diagnostic | 4 |
| Dietary | 4 |
| Digital | 4 |
| Discovery | 4 |
| Dominican | 4 |
| ECG | 4 |
| EDN | 4 |
| EI | 4 |
| Concern | 4 |
| CoA | 4 |
| Boscari | 4 |
| CDC | 4 |
| Box | 4 |
| Brazilian | 4 |
| British | 4 |
| CAM | 4 |
| CBHEC | 4 |
| CCK-1R | 4 |
| CD3 | 4 |
| CD56 | 4 |
| CH | 4 |
| Clerodendrum | 4 |
| CIRS | 4 |
| CNS | 4 |
| CORONADO | 4 |
| COVID‐19‐specific | 4 |
| CRFs | 4 |
| CRMP | 4 |
| Candida | 4 |
| Centers | 4 |
| ME | 4 |
| Long | 4 |
| Majoramputationen | 4 |
| VLCD | 4 |
| Timisoara | 4 |
| Torres | 4 |
| URL | 4 |
| Ukraine | 4 |
| Utility | 4 |
| VAT | 4 |
| VEGF-1 | 4 |
| VFA | 4 |
| Validation | 4 |
| Th17 | 4 |
| Vice | 4 |
| Vorteil | 4 |
| WAT | 4 |
| Wagner | 4 |
| Wochen | 4 |
| Y. | 4 |
| Yan | 4 |
| Z. | 4 |
| Thai | 4 |
| Test | 4 |
| Zhang | 4 |
| Steatosis | 4 |
| Signaling | 4 |
| Slovakia | 4 |
| Slovenia | 4 |
| Southeast | 4 |
| Sp | 4 |
| Sport | 4 |
| Stata | 4 |
| Statement | 4 |
| Superjami | 4 |
| Terminalia | 4 |
| Sustainability | 4 |
| Syndr | 4 |
| T3 | 4 |
| TAS | 4 |
| TORNASOL | 4 |
| TS | 4 |
| TW | 4 |
| Tamil | 4 |
| Zagazig | 4 |
| ZnT8A | 4 |
| Secretagogin | 4 |
| sind | 4 |
| pentoxifylline | 4 |
| peptidase-4 | 4 |
| preadipocytes | 4 |
| proinsulin | 4 |
| pts | 4 |
| quetiapine | 4 |
| range | 4 |
| schon | 4 |
| south | 4 |
| noch | 4 |
| streptozotocin | 4 |
| syndrome | 4 |
| teplizumab | 4 |
| tocilizumab | 4 |
| tropicalis | 4 |
| unter | 4 |
| wie | 4 |
| Malondialdehyde | 4 |
| normoglycemic | 4 |
| ng/ | 4 |
| Zoster | 4 |
| endothelin-1 | 4 |
| aber | 4 |
| american | 4 |
| apo | 4 |
| aspart | 4 |
| b. | 4 |
| behandelten | 4 |
| day | 4 |
| doc_id | 4 |
| fundoscopic | 4 |
| middle | 4 |
| g. | 4 |
| gegen | 4 |
| ghrelin | 4 |
| gr1 | 4 |
| kB | 4 |
| kürzlich | 4 |
| malondialdehyde | 4 |
| med | 4 |
| Shiraz | 4 |
| mn | 4 |
| Safety | 4 |
| Obstetrics | 4 |
| Non | 4 |
| Northern | 4 |
| Note | 4 |
| ODC | 4 |
| OHC | 4 |
| OS | 4 |
| OSI | 4 |
| Observational | 4 |
| Office | 4 |
| Natural | 4 |
| Oman | 4 |
| Open | 4 |
| Organisation | 4 |
| Outbreak | 4 |
| PBF | 4 |
| PGE | 4 |
| PI | 4 |
| PKB | 4 |
| Nile | 4 |
| Nadu | 4 |
| PSC | 4 |
| MetAP | 4 |
| Mass | 4 |
| SUA | 4 |
| McAllen | 4 |
| Med | 4 |
| Mediterranean | 4 |
| Mental | 4 |
| z. | 4 |
| Mercury | 4 |
| Metabolism | 4 |
| Nachweis | 4 |
| MgC | 4 |
| MgRC | 4 |
| Mn | 4 |
| Monaten | 4 |
| Multicenter | 4 |
| NETosis | 4 |
| NHLBI | 4 |
| NPH | 4 |
| PRISM | 4 |
| Miah | 4 |
| PTB | 4 |
| Reduktion | 4 |
| Resistin | 4 |
| Retrospective | 4 |
| Riesgo | 4 |
| Rosuva | 4 |
| Royal | 4 |
| Rural | 4 |
| Russia | 4 |
| S100A8 | 4 |
| SDS | 4 |
| SES | 4 |
| SFA | 4 |
| SHBG | 4 |
| SIBO | 4 |
| SLE | 4 |
| SNPs | 4 |
| SPB | 4 |
| Pb | 4 |
| STEMI | 4 |
| STATA | 4 |
| Regensburg | 4 |
| SG | 4 |
| Populations | 4 |
| Project | 4 |
| Pima | 4 |
| Real | 4 |
| Pharmacy | 4 |
| Plan | 4 |
| Policlinico | 4 |
| Prevotella | 4 |
| Programme | 4 |
| Programming | 4 |
| Phase | 4 |
| Prospective | 4 |
| RB | 4 |
| Rapid | 4 |
| Province | 4 |
| Publisher | 4 |
| Pulmonary | 4 |
| Protection | 4 |
| Qualitative | 4 |
| Gynaecologist | 3 |
| Guideline | 3 |
| GraphPad | 3 |
| Glycemia | 3 |
| Glycation | 3 |
| Gian | 3 |
| Glukosetoleranz | 3 |
| Genetic | 3 |
| Gegensatz | 3 |
| García | 3 |
| HBP | 3 |
| GI | 3 |
| GS | 3 |
| Hyperuricemia | 3 |
| HM | 3 |
| HCHF | 3 |
| HCV | 3 |
| HDLC | 3 |
| HGP | 3 |
| HID | 3 |
| HIIT | 3 |
| HIR | 3 |
| HSD1 | 3 |
| HSP70 | 3 |
| Hatieganu | 3 |
| Havana | 3 |
| Heinonen | 3 |
| Heparin | 3 |
| GC | 3 |
| Hunan | 3 |
| GHA | 3 |
| FG | 3 |
| GADA | 3 |
| FIB-4 | 3 |
| EUROSTAT | 3 |
| IBM | 3 |
| Elevated | 3 |
| Empowerment | 3 |
| Enfermedades | 3 |
| Enterococcus | 3 |
| Entwicklung | 3 |
| Erythrocyte | 3 |
| Es | 3 |
| EuGlA | 3 |
| Extremitäten | 3 |
| Eye | 3 |
| FFAs | 3 |
| FGF21 | 3 |
| FINRISK | 3 |
| G-2548A | 3 |
| FVII | 3 |
| Fadini | 3 |
| Fat | 3 |
| Federal | 3 |
| Federico | 3 |
| Fiber | 3 |
| Finnish | 3 |
| Flood | 3 |
| Flu | 3 |
| Follow | 3 |
| Framingham | 3 |
| French | 3 |
| Frühstadium | 3 |
| Funnell | 3 |
| IA-2A | 3 |
| Kumar | 3 |
| ICA | 3 |
| LPO | 3 |
| Ji | 3 |
| KDIGO | 3 |
| KNHANES | 3 |
| Kinesiology | 3 |
| King | 3 |
| Koreans | 3 |
| LA | 3 |
| LADA | 3 |
| LCACoA | 3 |
| LD | 3 |
| LDLR | 3 |
| LEPRGln223Arg | 3 |
| LH | 3 |
| LMGB | 3 |
| Lactobacillus | 3 |
| ICUs | 3 |
| Lasertherapie | 3 |
| Latina | 3 |
| Lee | 3 |
| Level | 3 |
| Levels | 3 |
| Li | 3 |
| Lincoln | 3 |
| Lipoprotein | 3 |
| Litchman | 3 |
| Lixandru | 3 |
| Loneliness | 3 |
| Longa | 3 |
| Loss | 3 |
| ERK1/2 | 3 |
| Jahren | 3 |
| JMIR | 3 |
| JBDS | 3 |
| J.C. | 3 |
| IG | 3 |
| IL | 3 |
| IL-17A | 3 |
| IL-1b | 3 |
| IL6 | 3 |
| ILC3s | 3 |
| IMCL | 3 |
| IMM | 3 |
| IPA | 3 |
| IPAQ | 3 |
| IRI | 3 |
| IRP | 3 |
| IRS1 | 3 |
| IUFD | 3 |
| IVGTT | 3 |
| Igs | 3 |
| Il1-β | 3 |
| Illness | 3 |
| Immunohistochemistry | 3 |
| Inc | 3 |
| Incidence | 3 |
| Increased | 3 |
| Individualized | 3 |
| Inflammation | 3 |
| Insoles | 3 |
| Instituto | 3 |
| Interactive | 3 |
| Italian | 3 |
| Iuliu | 3 |
| ESR1 | 3 |
| Beginn | 3 |
| EPA | 3 |
| Brasil | 3 |
| Atorvastatin | 3 |
| Attenuates | 3 |
| Auch | 3 |
| Autoantikörpern | 3 |
| Avogaro | 3 |
| BF% | 3 |
| BKS | 3 |
| BW | 3 |
| Bacteroides | 3 |
| Bangalore | 3 |
| Bavaria | 3 |
| Bax | 3 |
| MAP | 3 |
| Blue | 3 |
| Bratislava | 3 |
| EMA | 3 |
| Business | 3 |
| C.S. | 3 |
| CABG | 3 |
| CAMDI | 3 |
| CASALUD | 3 |
| CCR2 | 3 |
| CFS | 3 |
| CG | 3 |
| CODE-2 | 3 |
| COVID- | 3 |
| COX | 3 |
| CV | 3 |
| CV% | 3 |
| CaMKK | 3 |
| Asian | 3 |
| Artery | 3 |
| Apoptosis | 3 |
| Apolipoprotein | 3 |
| 2max | 3 |
| > | 3 |
| A.A. | 3 |
| AA | 3 |
| ACE1 | 3 |
| ACM | 3 |
| ADP | 3 |
| AGE | 3 |
| AGTMS | 3 |
| AI | 3 |
| APACHE | 3 |
| ATH | 3 |
| Aborigines | 3 |
| Active | 3 |
| Activities | 3 |
| Acute | 3 |
| Adherence | 3 |
| Adipocyte | 3 |
| Adoption | 3 |
| Affiliated | 3 |
| Agonists | 3 |
| Andhra | 3 |
| Animal | 3 |
| Annual | 3 |
| Anthropometric | 3 |
| Anthropometry | 3 |
| Antidepressant | 3 |
| Antikörper | 3 |
| Apigenin | 3 |
| Cairo | 3 |
| California | 3 |
| Canadians | 3 |
| DI | 3 |
| DRW | 3 |
| DSG | 3 |
| DSMES | 3 |
| DT2 | 3 |
| Dabei | 3 |
| Daily | 3 |
| Das | 3 |
| De | 3 |
| Density | 3 |
| Developmental | 3 |
| Dexcom | 3 |
| Diabetesremission | 3 |
| Diabetologists | 3 |
| Diagnosis | 3 |
| Diason | 3 |
| Die | 3 |
| Direct | 3 |
| Disability | 3 |
| Disorder | 3 |
| Disorders | 3 |
| Disparities | 3 |
| Division | 3 |
| Diät | 3 |
| Durre | 3 |
| EBSCO | 3 |
| EBV | 3 |
| EDHF | 3 |
| EDS | 3 |
| EGP | 3 |
| DM-2 | 3 |
| DHA | 3 |
| Cancer | 3 |
| DDS2 | 3 |
| Capacity | 3 |
| Carbohydrate | 3 |
| Carboxypeptidase | 3 |
| Cardiometabolic | 3 |
| Caribbean | 3 |
| Carlos | 3 |
| Caspase-3 | 3 |
| Catholic | 3 |
| Cenicriviroc | 3 |
| Chicago | 3 |
| ClinicalTrials.gov | 3 |
| Clozapine | 3 |
| Cocreation | 3 |
| Combination | 3 |
| Congress | 3 |
| Content | 3 |
| Continuous | 3 |
| Cook | 3 |
| Coronary | 3 |
| Cost | 3 |
| Countries | 3 |
| Country | 3 |
| Cr | 3 |
| Cuba | 3 |
| Current | 3 |
| Customer | 3 |
| DA | 3 |
| DAT | 3 |
| DCs | 3 |
| M.S. | 3 |
| Biguanide | 3 |
| MAPK | 3 |
| WM | 3 |
| Tripoli | 3 |
| Tropical | 3 |
| Troponin | 3 |
| UCLA | 3 |
| Umberto | 3 |
| Universitario | 3 |
| Urban | 3 |
| VIGITEL | 3 |
| VZV | 3 |
| Veterans | 3 |
| Viral | 3 |
| WACDD | 3 |
| WCM | 3 |
| WG | 3 |
| WT | 3 |
| bp | 3 |
| Waist | 3 |
| Working | 3 |
| Zellen | 3 |
| Zimmet | 3 |
| Zü | 3 |
| acarbose | 3 |
| adipokine | 3 |
| aldosterone | 3 |
| anderen | 3 |
| angiotensinogen | 3 |
| aripiprazole | 3 |
| atorvastatin | 3 |
| ausgeprägt | 3 |
| azithromycin | 3 |
| Treatments | 3 |
| Traditional | 3 |
| Tongji | 3 |
| Tissue | 3 |
| Spanish | 3 |
| Spike | 3 |
| Standardtherapie | 3 |
| Statistical | 3 |
| Strandvik | 3 |
| Strategy | 3 |
| Structure | 3 |
| Structured | 3 |
| Student | 3 |
| Survival | 3 |
| Systemic | 3 |
| TEDDY | 3 |
| TGR5 | 3 |
| TJ | 3 |
| TLR4 | 3 |
| TNF-2 | 3 |
| TNFa | 3 |
| TRC | 3 |
| TWO2 | 3 |
| Tab | 3 |
| Tabriz | 3 |
| Target | 3 |
| Targeting | 3 |
| Teilnehmer | 3 |
| Telehealth | 3 |
| Telmisartan | 3 |
| Testing | 3 |
| Thailand | 3 |
| Therapien | 3 |
| behandelt | 3 |
| bw | 3 |
| Sleep | 3 |
| rs9939609 | 3 |
| miRNA | 3 |
| microRNAs | 3 |
| ml*min | 3 |
| mm | 3 |
| nachgewiesen | 3 |
| normoalbuminuria | 3 |
| north | 3 |
| oligomenorrhea | 3 |
| p1 | 3 |
| p<.001 | 3 |
| pg | 3 |
| publizierten | 3 |
| receptor-1 | 3 |
| remdesivir | 3 |
| sBP | 3 |
| c. | 3 |
| sVCAM-1 | 3 |
| schweren | 3 |
| sulfonylurea | 3 |
| syndrom | 3 |
| tPA | 3 |
| tele | 3 |
| thrombophilia | 3 |
| vasculopathy | 3 |
| verhindern | 3 |
| weiteren | 3 |
| | | 3 |
| À0.24 | 3 |
| −/− | 3 |
| MBI | 3 |
| methotrexate | 3 |
| losartan | 3 |
| lm | 3 |
| liegt | 3 |
| cTnI | 3 |
| cenicriviroc | 3 |
| china | 3 |
| chow | 3 |
| controll | 3 |
| covid-19 | 3 |
| department | 3 |
| diabetes-2020 | 3 |
| diabetic | 3 |
| didn′t | 3 |
| dipeptidyl | 3 |
| dipyridamole | 3 |
| disease-2019 | 3 |
| e. | 3 |
| eines | 3 |
| epidydimis | 3 |
| es | 3 |
| frühen | 3 |
| gegenüber | 3 |
| glibenclamide | 3 |
| hepatitis | 3 |
| hinweg | 3 |
| inhospital | 3 |
| insbesondere | 3 |
| klinischen | 3 |
| konnten | 3 |
| könnte | 3 |
| lateralis | 3 |
| licogliflozin | 3 |
| Soc | 3 |
| cotransporter-2 | 3 |
| Sitagliptin | 3 |
| OW | 3 |
| NIRS | 3 |
| NW | 3 |
| NZO | 3 |
| Nacional | 3 |
| Natriuretic | 3 |
| Nauru | 3 |
| Nephropathy | 3 |
| Neuropathic | 3 |
| Nicaragua | 3 |
| Nutrison | 3 |
| O. | 3 |
| OECD | 3 |
| OHA | 3 |
| OMM | 3 |
| October | 3 |
| PTEN | 3 |
| Omentin | 3 |
| Ongoing | 3 |
| PAV | 3 |
| PCI | 3 |
| PCT | 3 |
| PCr | 3 |
| PHC | 3 |
| PHS | 3 |
| PI3-K | 3 |
| PN | 3 |
| POInT | 3 |
| PP | 3 |
| PPARc2 | 3 |
| PPV | 3 |
| NIDNMD | 3 |
| NHANES | 3 |
| NGTMS | 3 |
| NFS | 3 |
| MBL | 3 |
| Signed | 3 |
| MD | 3 |
| MDRD | 3 |
| MPC | 3 |
| MPO | 3 |
| MRC | 3 |
| MS(+ | 3 |
| Magnesium | 3 |
| Mainland | 3 |
| Managing | 3 |
| Martinez | 3 |
| Mashhad | 3 |
| Measures | 3 |
| Medication | 3 |
| MetSy | 3 |
| MetSyn | 3 |
| Mg | 3 |
| MgR | 3 |
| Milan | 3 |
| Misra | 3 |
| Mit | 3 |
| Mobile | 3 |
| Monate | 3 |
| Multinational | 3 |
| Munich | 3 |
| NAFLD(+ | 3 |
| NAS | 3 |
| NC | 3 |
| PRT | 3 |
| NFκB | 3 |
| Pan | 3 |
| SVneo | 3 |
| Rep | 3 |
| Reproduction | 3 |
| Res | 3 |
| Risiko | 3 |
| Robust | 3 |
| Role | 3 |
| Rosi | 3 |
| Roux | 3 |
| S.M. | 3 |
| SAS | 3 |
| SCFA | 3 |
| SF-36 | 3 |
| SGLT2i | 3 |
| SSB | 3 |
| Sacred | 3 |
| Register | 3 |
| Salamanca | 3 |
| Salmonella | 3 |
| Santa | 3 |
| Sauerstofftherapie | 3 |
| Sc | 3 |
| Scholar | 3 |
| Scopus | 3 |
| Sensor | 3 |
| Sensors | 3 |
| Series | 3 |
| Serum | 3 |
| Pancreas | 3 |
| Shahid | 3 |
| Shi | 3 |
| Remote | 3 |
| SREBP1 | 3 |
| Recommendations | 3 |
| Pio | 3 |
| Preeclampsia | 3 |
| Predictors | 3 |
| Pre | 3 |
| Pradesh | 3 |
| Platform | 3 |
| Placenta | 3 |
| Piette | 3 |
| ProQuest | 3 |
| Pharmacology | 3 |
| Pharmacological | 3 |
| Rd | 3 |
| Personalized | 3 |
| Peroxisome | 3 |
| Peer | 3 |
| Prism | 3 |
| Planning | 3 |
| RP | 3 |
| RCTs | 3 |
| RW | 3 |
| Proliferator | 3 |
| RN | 3 |
| RG | 3 |
| RDS | 3 |
| Rat | 3 |
| RCT | 3 |
| RAAS | 3 |
| Protocol | 3 |
| Proteus | 3 |
| Protective | 3 |
| IAA | 2 |
| Humanin | 2 |
| Hispanic | 2 |
| Histone | 2 |
| Horizonte | 2 |
| Hormones | 2 |
| Hippocampal | 2 |
| Hypoglykämien | 2 |
| Humoral | 2 |
| Hurricane | 2 |
| Hussain | 2 |
| Hydrogen | 2 |
| Hyperglycemia | 2 |
| Hyperlipidemia | 2 |
| Hypertriglyceridemia | 2 |
| Hier | 2 |
| Hill | 2 |
| HP | 2 |
| Hepatocellular | 2 |
| Hemoglobin | 2 |
| HIV-1 | 2 |
| ICAM-1 | 2 |
| HIE | 2 |
| HLP | 2 |
| HMG | 2 |
| HPA | 2 |
| HQRoL | 2 |
| HRQoL | 2 |
| HRT | 2 |
| HSCs | 2 |
| HTR8 | 2 |
| HVA | 2 |
| Hasanuddin | 2 |
| Haya | 2 |
| HealthKick | 2 |
| IBSAL | 2 |
| Independent | 2 |
| ICV | 2 |
| ITT | 2 |
| Ill | 2 |
| Imaging | 2 |
| Immunity | 2 |
| Immunology | 2 |
| Improvement | 2 |
| Improvements | 2 |
| Improving | 2 |
| Imputation | 2 |
| Inc. | 2 |
| Indigenous | 2 |
| Injections | 2 |
| Innovation | 2 |
| Inquiry | 2 |
| HEGC | 2 |
| Inselautoimmunität | 2 |
| IVF | 2 |
| IST | 2 |
| ID | 2 |
| ISR | 2 |
| IDMPS | 2 |
| IFD | 2 |
| IGI | 2 |
| IHC | 2 |
| IL-1 | 2 |
| IL-12 | 2 |
| IL-33 | 2 |
| IL-7 | 2 |
| IM | 2 |
| IOM | 2 |
| IPM | 2 |
| IRB20200404 | 2 |
| IRCCS | 2 |
| IRX5 | 2 |
| ISPAD | 2 |
| HHEX | 2 |
| FVC | 2 |
| HDLs | 2 |
| Fußsyndrom | 2 |
| Findings | 2 |
| Force | 2 |
| Formulations | 2 |
| Fos | 2 |
| Fr | 2 |
| Francesco | 2 |
| Fund | 2 |
| Fußulkus | 2 |
| HDLcholesterol | 2 |
| Fußulzera | 2 |
| Fälle | 2 |
| G-308A | 2 |
| GCS | 2 |
| GGTP | 2 |
| GIGD | 2 |
| GIR | 2 |
| Filipinos | 2 |
| Fibromax | 2 |
| Features | 2 |
| Farnsworth | 2 |
| Insurance | 2 |
| FABPpm | 2 |
| FF | 2 |
| FFM | 2 |
| FFQ | 2 |
| FGIR | 2 |
| FI | 2 |
| FINDRISK | 2 |
| FIO2 | 2 |
| FSFI | 2 |
| FVIII | 2 |
| Fact | 2 |
| Factor | 2 |
| Faecalibacterium | 2 |
| Failure | 2 |
| GIT | 2 |
| GLP-1RA | 2 |
| GLP-1RAs | 2 |
| Grade | 2 |
| Group-2 | 2 |
| Group-3 | 2 |
| Groups | 2 |
| Guadalajara | 2 |
| Gulf | 2 |
| Gutierrez | 2 |
| Gâr | 2 |
| H2 | 2 |
| HAC | 2 |
| HB | 2 |
| HBO | 2 |
| HCL | 2 |
| HCPs | 2 |
| HD | 2 |
| HDLc | 2 |
| Green | 2 |
| Goto | 2 |
| GLP-2 | 2 |
| Good | 2 |
| GLUT-4 | 2 |
| GP | 2 |
| GPPAD | 2 |
| GPPAQ | 2 |
| Gabriele | 2 |
| Gaetano | 2 |
| Gamma | 2 |
| Garcia | 2 |
| Gene | 2 |
| Geneva | 2 |
| Genomic | 2 |
| Gerontology | 2 |
| Gewichtsreduktion | 2 |
| Ghana | 2 |
| Giuseppe | 2 |
| Insulinproduktion | 2 |
| Moriski | 2 |
| Interactions | 2 |
| Mat | 2 |
| Malaria | 2 |
| Mandala | 2 |
| Mandarin | 2 |
| Maring | 2 |
| Market | 2 |
| Mas | 2 |
| Masson | 2 |
| Matteo | 2 |
| MAGDA | 2 |
| Mauritians | 2 |
| Mauritius | 2 |
| McAuley | 2 |
| Medica | 2 |
| Medicina | 2 |
| Mehta | 2 |
| Meier | 2 |
| Malappuram | 2 |
| Makassar | 2 |
| Maiorescu | 2 |
| Made | 2 |
| MC4R | 2 |
| MDD | 2 |
| MEK | 2 |
| MHC | 2 |
| MIE | 2 |
| MIGRANT | 2 |
| MII | 2 |
| MIP-2 | 2 |
| MPHR | 2 |
| MT1P3 | 2 |
| MTT | 2 |
| MUFA | 2 |
| MVA | 2 |
| MVA1 | 2 |
| MYD88 | 2 |
| Mensing | 2 |
| Meri | 2 |
| Met | 2 |
| Multimorbidity | 2 |
| Muscat | 2 |
| Muslims | 2 |
| Myeloperoxidase | 2 |
| Myocardial | 2 |
| Mü | 2 |
| N.C. | 2 |
| nan | 2 |
| NAFLD(À | 2 |
| NCD | 2 |
| NEJM | 2 |
| NF- | 2 |
| NFAT | 2 |
| NFkB | 2 |
| NLRP3 | 2 |
| NMR | 2 |
| Multivariate | 2 |
| Mountains | 2 |
| Method | 2 |
| Mother | 2 |
| Metropolitan | 2 |
| Michael | 2 |
| MicroRNAs | 2 |
| Microbiol | 2 |
| Microbiota | 2 |
| Microvascular | 2 |
| Millipore | 2 |
| Mini | 2 |
| Minocycline | 2 |
| Mitigation | 2 |
| Mitochondria | 2 |
| Modeling | 2 |
| Mohammed | 2 |
| Montes | 2 |
| Experimental | 2 |
| MALDI | 2 |
| M2 | 2 |
| Interim | 2 |
| Kadoorie | 2 |
| Jewell | 2 |
| Jiangsu | 2 |
| Jiaotong | 2 |
| Joint | 2 |
| KAUH | 2 |
| KSCDC | 2 |
| Kabelitz | 2 |
| Kakizaki | 2 |
| Ländern | 2 |
| Kalantar | 2 |
| Kansra | 2 |
| Kaplan | 2 |
| Kaposi | 2 |
| Kasralainy | 2 |
| Katrina | 2 |
| Kenneth | 2 |
| Janus | 2 |
| Janeiro | 2 |
| Jabeen | 2 |
| JNK | 2 |
| Interval | 2 |
| Intra | 2 |
| Intravenous | 2 |
| Inventory | 2 |
| Involvement | 2 |
| Iraq | 2 |
| Irisin | 2 |
| Islet | 2 |
| Isocaloric | 2 |
| Isolated | 2 |
| Item | 2 |
| IvGTT | 2 |
| J.Z | 2 |
| JAK2 | 2 |
| JIS | 2 |
| Kerala | 2 |
| Ketoacidosis | 2 |
| Khader | 2 |
| LVMI | 2 |
| Lanifibranor | 2 |
| Lean | 2 |
| Led | 2 |
| Letter | 2 |
| Libre | 2 |
| License | 2 |
| Lifestyle | 2 |
| Like | 2 |
| Lin | 2 |
| Lipogenesis | 2 |
| Literature | 2 |
| Liverpool | 2 |
| Local | 2 |
| Lockdown | 2 |
| Lopez | 2 |
| Langerhans | 2 |
| LVEF | 2 |
| Ki | 2 |
| LVEDD | 2 |
| Kinder | 2 |
| Kistauri | 2 |
| Knies | 2 |
| Kohlenhydraten | 2 |
| Kopp | 2 |
| Kosova | 2 |
| Kost | 2 |
| Kutaisi | 2 |
| LAGB | 2 |
| LAP | 2 |
| LBM | 2 |
| LHRH | 2 |
| LKB1 | 2 |
| LSH | 2 |
| LV | 2 |
| Expertise | 2 |
| Cellular | 2 |
| Experiences | 2 |
| Barriers | 2 |
| BPV | 2 |
| BUN | 2 |
| Babes | 2 |
| Babol | 2 |
| Baca | 2 |
| Bacteremia | 2 |
| Bangladesh | 2 |
| Baseline | 2 |
| Atashzar | 2 |
| BbsI | 2 |
| Beauty | 2 |
| Bedfordshire | 2 |
| Beheshti | 2 |
| Beitrag | 2 |
| Belo | 2 |
| Berberine | 2 |
| BMI>=24 | 2 |
| BMI23 | 2 |
| BMD | 2 |
| BL | 2 |
| AusDiab | 2 |
| Australasian | 2 |
| Australians | 2 |
| Author | 2 |
| AutoCM | 2 |
| Autoantikörper | 2 |
| Autoimmune | 2 |
| Ayurveda | 2 |
| Azithromycin | 2 |
| B2 | 2 |
| BAAT | 2 |
| BACKGROUND | 2 |
| BALB | 2 |
| BCG | 2 |
| BDNF | 2 |
| Berezin | 2 |
| Bhutias | 2 |
| Biological | 2 |
| CAT | 2 |
| CCK | 2 |
| CCK-2R | 2 |
| CCR5 | 2 |
| CD59 | 2 |
| CGD | 2 |
| CH4 | 2 |
| CK | 2 |
| CK18 | 2 |
| CM | 2 |
| CMV | 2 |
| CNCS | 2 |
| CNPq | 2 |
| CO | 2 |
| COVID-!9 | 2 |
| COVID-2019 | 2 |
| CBG | 2 |
| CARO | 2 |
| Biomarker | 2 |
| C57BL/6J | 2 |
| Biomedical | 2 |
| Biotechnology | 2 |
| Birjand | 2 |
| Bisphenol | 2 |
| Border | 2 |
| Borrelia | 2 |
| Boston | 2 |
| Br | 2 |
| Brain | 2 |
| Brazilians | 2 |
| Breast | 2 |
| Breath | 2 |
| Brussels | 2 |
| Bruttomesso | 2 |
| C1q | 2 |
| Attachment | 2 |
| Associations | 2 |
| Expenditure | 2 |
| APO | 2 |
| AIIMS | 2 |
| AIP | 2 |
| AIx | 2 |
| AKI | 2 |
| AM | 2 |
| ANIAD | 2 |
| AOA | 2 |
| APTT | 2 |
| Assoc | 2 |
| ARM | 2 |
| ASAT | 2 |
| ATPase | 2 |
| Abdul | 2 |
| Abdullah | 2 |
| Aberdeen | 2 |
| Abfall | 2 |
| AIH | 2 |
| AIDS | 2 |
| AIC | 2 |
| AGT | 2 |
| NRS | 2 |
| -8 | 2 |
| 192QQ | 2 |
| 1C | 2 |
| 30dAS | 2 |
| A-1 | 2 |
| A1C | 2 |
| A8 | 2 |
| AAA | 2 |
| AACE | 2 |
| AAR | 2 |
| ABDC | 2 |
| ADIFIT | 2 |
| ADJ | 2 |
| ADRB1 | 2 |
| Abheilung | 2 |
| Abs | 2 |
| Acceptability | 2 |
| Alzheimer | 2 |
| Amputation | 2 |
| América | 2 |
| Anderson | 2 |
| Angebot | 2 |
| Anna | 2 |
| Anoop | 2 |
| Antenatal | 2 |
| Anwendung | 2 |
| ApoE | 2 |
| Applied | 2 |
| Arab | 2 |
| Arabs | 2 |
| Army | 2 |
| Arnhem | 2 |
| Arterial | 2 |
| Amazon | 2 |
| Altern | 2 |
| Accumulation | 2 |
| Alle | 2 |
| Acetyl | 2 |
| Ad | 2 |
| Adipose | 2 |
| Adipositas | 2 |
| Adiposity | 2 |
| Adjusted | 2 |
| Adolescents | 2 |
| Adverse | 2 |
| Affairs | 2 |
| Aflibercept | 2 |
| Akhtar | 2 |
| Akkermansia | 2 |
| Albania | 2 |
| Alberta | 2 |
| Alberto | 2 |
| COncise | 2 |
| CPT1A | 2 |
| CRS | 2 |
| Diabetesinzidenz | 2 |
| Depressive | 2 |
| Design | 2 |
| Dev | 2 |
| Devices | 2 |
| Diab | 2 |
| Diabet | 2 |
| Diabete | 2 |
| Diabetol | 2 |
| CSF | 2 |
| Diastolic | 2 |
| Differences | 2 |
| Discover | 2 |
| Disord | 2 |
| Distress | 2 |
| Djukic | 2 |
| Dominant | 2 |
| Dependent | 2 |
| Dengue | 2 |
| Dementia | 2 |
| Definition | 2 |
| D1 | 2 |
| DAN | 2 |
| DMARD | 2 |
| DMT1 | 2 |
| DNs | 2 |
| DPP-4I | 2 |
| DT | 2 |
| DXA | 2 |